Syncona sells Gyroscope to Novartis for up to $1.5bn
Syncona Limited NPV
123.40p
16:40 18/04/24
-0.48%
-0.60p
Syncona on Wednesday said it had sold its portfolio company Gyroscope Therapeutics Holdings to Novartis for up to $1.5bn (£1.1bn) on a cash and debt free basis.
Equity Investment Instruments
11,533.52
17:14 18/04/24
0.42%
48.68
FTSE 250
19,450.67
17:14 18/04/24
n/a
n/a
FTSE 350
4,334.00
17:14 18/04/24
n/a
n/a
FTSE All-Share
4,290.02
16:54 18/04/24
n/a
n/a
The company said it would receive an upfront payment of $800m, with another $700m potentially on offer via milestone payments related to clinical development, regulatory approvals and reimbursement.
On closing, the deal is expected to result in cash proceeds of £334m for Syncona, representing a £180m uplift to previous valuation and internal rate of return of 55%.
The sale could also generate a further £255m through future milestone payments, which if received would take total proceeds to £589m.